drugset

drugset / Trial / NCT07060989

A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

NCT07060989 ↗

Phase 1/2 Recruiting 220 enrolled Nutshell Therapeutics (Shanghai) Co., LTD.

NaSingle-groupOpen-labelTreatment

Summary

This study is to evaluate the safety, tolerability, PK, and preliminary efficacy of NTS071 in adults with TP53 Y220C-mutated solid tumors.

Timeline

Start: 2025-08-04
Primary completion: 2028-12
Completion: 2029-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NTS071	Unknown	—	Oral

Indications